SCHEMBL13551195

COc1cc(C)c(S(=O)(=O)N[C@@H](CC(=O)NCCCC(=O)NCCOCCOCCOCCO[C@H]2[C@H](OC)[C@@H](OC)[C@@H](O[C@H]3[C@H](OC)[C@@H](OC)[C@H](O[C@H]4[C@H](OS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@@H](O[C@H]5[C@H](OC)[C@@H](OC)[C@H](O[C@H]6[C@H](OC)[C@@H](OS(=O)(=O)O)[C@@H](OC)O[C@@H]6COS(=O)(=O)O)O[C@H]5C(=O)O)O[C@@H]4COS(=O)(=O)O)O[C@@H]3C(=O)O)O[C@@H]2COS(=O)(=O)O)C(=O)N[C@H](Cc2ccc(C(=N)N)cc2)C(=O)N2CCCCC2)c(C)c1C

nearest known ligand 0.57

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	F2	P00734	1/20	0.57

▸	PLG	P00747	1/20	0.38

▸	AVPR1B	P47901	6/20	0.36

▸	SERPINC1	P01008	1/20	0.35

▸	AVPR1A	P37288	4/20	0.33

▸	ST14	Q9Y5Y6	2/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL14959577	0.92	F2 (0.48)	F2PLGAVPR1BSERPINC1AVPR1A
SCHEMBL29589310	0.91	F2 (0.49)	F2PLG
SCHEMBL16085110	0.86	F2 (0.48)	F2PLG
SCHEMBL4732411	0.81	F2 (0.46)	F2PLGAVPR1BSERPINC1AVPR1A
SCHEMBL14959645	0.81	PLG (0.52)	PLGAVPR1BAVPR1AST14
SCHEMBL4732589	0.78	F2 (0.42)	F2
SCHEMBL12799348	0.78	F2 (0.45)	F2PLG
SCHEMBL12799315	0.78	F2 (0.45)	F2PLG
SCHEMBL6461917	0.78	PLG (0.54)	PLGAVPR1BAVPR1A
SCHEMBL6461926	0.78	PLG (0.54)	PLGAVPR1BAVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20100004186-A1	Antithrombotic Dual Inhibitors Comprising A Biotin Residue	N.V. ORGANON (NL)	2010-01-07	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100004186-A1	Antithrombotic Dual Inhibitors Comprising A Biotin Residue	SERPINC1, BRS3, TBXA2R	F2 69/4885PLG 495/4885AVPR1B 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.